Convalescent plasma for preventing critical illness in COVID-19: A phase 2 trial and immune profile

RATIONALE: The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring rapid adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising treatment that can be mobilized rapidly in a pandemic s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:medRxiv
Main Authors: Sturek, Jeffrey M., Thomas, Tania A., Gorham, James D., Sheppard, Chelsea A., Raymond, Allison E., Guex, Kristen Petros De, Harrington, William B., Barros, Andrew J., Madden, Gregory R., Alkabab, Yosra M., Lu, David, Liu, Qin, Poulter, Melinda D., Mathers, Amy J., Thakur, Archana, Kubicka, Ewa M., Lum, Lawrence G., Heysell, Scott K.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7899478/
https://ncbi.nlm.nih.gov/pubmed/33619508
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.02.16.21251849
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados